| 000 | 01889 a2200517 4500 | ||
|---|---|---|---|
| 005 | 20250514160623.0 | ||
| 264 | 0 | _c20040323 | |
| 008 | 200403s 0 0 eng d | ||
| 022 | _a1042-8194 | ||
| 024 | 7 |
_a10.1080/1042819031000083019 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aButt, Nauman M | |
| 245 | 0 | 0 |
_aCD34 positive selection as prophylaxis against graft versus host disease in allogeneic peripheral blood stem cell transplantation. _h[electronic resource] |
| 260 |
_bLeukemia & lymphoma _cSep 2003 |
||
| 300 |
_a1509-13 p. _bdigital |
||
| 500 | _aPublication Type: Evaluation Study; Journal Article | ||
| 650 | 0 | 4 | _aAcute Disease |
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAntigens, CD34 _xanalysis |
| 650 | 0 | 4 |
_aCyclophosphamide _xadministration & dosage |
| 650 | 0 | 4 |
_aCyclosporine _xtherapeutic use |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aGraft Survival |
| 650 | 0 | 4 |
_aGraft vs Host Disease _xetiology |
| 650 | 0 | 4 |
_aHematopoietic Stem Cells _ximmunology |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aImmunomagnetic Separation |
| 650 | 0 | 4 | _aImmunophenotyping |
| 650 | 0 | 4 |
_aImmunosuppressive Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aLeucovorin _xtherapeutic use |
| 650 | 0 | 4 |
_aLeukemia, Myeloid _xtherapy |
| 650 | 0 | 4 |
_aLymphocyte Depletion _xmethods |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMethotrexate _xtherapeutic use |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aPeripheral Blood Stem Cell Transplantation _xadverse effects |
| 650 | 0 | 4 |
_aT-Lymphocytes, Cytotoxic _ximmunology |
| 650 | 0 | 4 | _aTransplantation Conditioning |
| 650 | 0 | 4 |
_aTransplantation, Homologous _xadverse effects |
| 650 | 0 | 4 | _aWhole-Body Irradiation |
| 700 | 1 | _aMcGinnity, Noreen | |
| 700 | 1 | _aClark, Richard E | |
| 773 | 0 |
_tLeukemia & lymphoma _gvol. 44 _gno. 9 _gp. 1509-13 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1080/1042819031000083019 _zAvailable from publisher's website |
| 999 |
_c14308407 _d14308407 |
||